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LABORATORY DIAGNOSIS FOR DENGUE 
Marli Tenório CORDEIRO(1)
Effective epidemiological surveillance for dengue fever must 
include the ability of routine laboratory confirmation and monitoring 
of circulating serotypes. Laboratory surveillance is essential so that 
differential diagnosis could be performed between dengue fever and other 
acute febrile diseases, due to clinical similarities exhibited. 
In general, the dengue´s laboratory diagnosis aims: 1) laboratory, 
serologic and/or virologic infection´s confirmation; 2) identification of 
circulating serotypes; 3) laboratory confirmation of severe and fatal cases; 
4) support for epidemiological investigations to determine the levels of 
disease transmission and 5) performance of molecular studies in order to 
identify existing genotypes in the region (VORNDAM & KUNO, 1997). 
For adequate effectiveness of the laboratory diagnosis, it is required to 
take into account the appropriate time for blood sampling and to what 
type of test it is designated. This information is of great importance when 
interpreting the results.
Laboratory criteria for confirmation of cases
The positive results for one of the following methods will confirm the 
case by laboratory criterion: 1) isolation and identification of dengue virus 
(DENV) in blood sample (serum, plasma), organ fragments collected post 
mortem (liver, spleen, kidney, heart, lung, nervous system); 2) detection 
of viral nucleic acid (RNA) using the reverse transcription-polymerase 
chain reaction (RT-PCR) technique; 3) detection of non-structural 1 
(NS1) protein (antigen) in serum and/or plasma sample; 4) detection of 
IgM antibodies specific for dengue in a single serum sample; 5) increase 
of four times or more in the IgG antibodies titers; hemagglutination 
inhibiting antibodies, and/or neutralizing antibodies in paired serum 
samples, collected during the acute phase of illness and convalescence, 
for one or more DENV antigens; 6) demonstration of viral antigen in 
necropsied tissues by immunohistochemistry (WHO, 1997; GUZMAN 
& KOURI, 2004). 
Virologic diagnosis
For isolation of the virus, the blood collection should be performed 
preferably within the first five to six days of symptoms, during the acute 
phase. This sample will also be used for detection of viral RNA by RT-
PCR, for real time RT-PCR and also for detection of NS1 antigen. Virus 
isolation is performed usually in cell cultures of mosquito (clone C6/36, 
Aedes albopictus; TRA-284, Toxorhynchites amboinenses and AP-61, 
Aedes pseudoscutellaris), (IGARASHI, 1978). Continuous lines of 
vertebrates, such as VERO, BHK-21, LLC-MK2, and also inoculation 
into animals and mosquitos can also be used. The isolated viruses can be 
identified by indirect immunofluorescence using monoclonal antibodies 
against all four serotypes (HENCHAL et al., 1982). 
Molecular diagnostics by RT-PCR
The extraction of viral RNA from the samples is carried out using 
in house techniques (Trisol, Silica/Guanidine isothiocyanate, etc), by 
column-extraction kits and automated equipment. For detection of 
viral RNA and identification of serotypes by RT-PCR technique, the 
protocol described by LANCIOTTI et al. (1992) has been one of the 
most used in the country. In this technique, universal primers are used 
for DENV located in the genes C and prM which have good sensitivity 
and specificity. This fragment is flanked by a sequence conserved among 
all DENV serotypes allowing genomic amplification. Serotype is then 
identified by using serotype-specific primers in a semi-nested PCR in a 
second amplification. The RT-PCR products (cDNA) can be viewed by 1% 
agarose gel electrophoresis, and then digitalized.
Real time RT-PCR, in addition to be more sensitive, has the advantage 
to be able to process a large number of samples at once, and be used both 
qualitatively and quantitatively (determination of viral load). 
The use of conventional RT-PCR in early diagnosis of suspected cases 
and to monitor viral circulation has proven to be a valuable diagnostic tool, 
with the advantage of not providing significant difference in sensitivity, in 
both primary and secondary cases, or even in the presence or absence of 
IgM in the serum sample tested (CORDEIRO et al., 2007). 
Detection of NS1 antigen
The hexameric form of NS1 protein is highly conserved in all four 
DENV serotypes and was found circulating in the blood of patients from 
the first to the ninth day after the onset of fever (YOUNG et al., 2000). 
Because it is present in the serum during the acute phase of the infection, 
NS1 antigen is a marker used in the early diagnosis of the disease, with 
a greater sensitivity in the first five days of disease. Detection of NS1 
by ELISA is rapid and as sensitive as RT-PCR, but does not distinguish 
the virus serotypes. 
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Moreover, the sensitivity of the test can vary depending on the type 
of infection. Results obtained in our studies using kit PlateliaTM Dengue 
NS1Ag-ELISA (BIORAD) demonstrated greater sensitivity in the 
confirmation of primary cases (94.0%; 94/100), compared to secondary 
ones (54.1%; 66/122) (p < 0.0001). Sensitivities of 97.5% and 59.1% 
for primary and secondary infections, respectively, were also observed 
by McBRIDE (2009). 
False-negative results can occur, and possibly result from the 
formation of immune complexes of NS1 antigen with IgG, particularly 
in secondary infections, where target antigens are no longer accessible to 
the monoclonal antibody from ELISA (HANG et al., 2009). Because NS1 
capture test is more effective in the acute phase of the disease, this could 
be used in combination with ELISA-IgM to increase detection sensitivity, 
particularly in areas of high prevalence of secondary infections. 
Serological diagnosis
Serological diagnosis detects specific antibodies to the virus and 
complements the virological diagnosis, and when this is not possible, it 
works as an alternative way for diagnosis. The detection of antibodies can 
be made using immunoenzymatic (ELISA) and immunochromatographic 
techniques; test for hemagglutination inhibition (HI), plaque reduction 
neutralization test (PRNT), etc. 
Specific antibodies IgM are produced temporarily, during both 
primary and secondary infection. Anti-dengue IgM can be detected, 
usually from the fifth day of disease and may persist for 60 to 90 days. 
Therefore, its detection in any serum sample is indicative of active or 
recent infection, within the last two to three months. The production of 
antibodies for DENV is usually distinct from those having primary and 
secondary infections. In the primary infection, IgM is usually detected 
from the fifth day of disease, while IgG is detected at low levels, generally 
from the seventh day after the onset of infection. Conversely, in the 
secondary infection, antibodies IgG are detected at high levels in acute 
phase, while antibodies IgM are usually detected in the lower titers than 
those observed in the primary infections (GUZMAN & KOURI, 2004).
Importantly, during a secondary infection (sequential), about 20% of 
patients do not have IgM at detectable levels and, therefore, it is required 
to perform other serological tests, such as hemagglutination inhibition test 
or plaque reduction neutralization test, to confirm the case (VORNDAM 
& KUNO, 1997). 
In the primary infection, relatively monotypic neutralizing antibodies 
are detected. In the secondary infections, high titers of neutralizing 
antibodies are produced to two or more of the four DENV serotypes. 
In some combinations of sequential infections, the highest titer for 
neutralizing antibodies in the serum of convalescent patient is targeted 
against the virus that infected earlier, a phenomenon called “original 
antigenic sin”, which can sometimes hamper the interpretation of the 
serological test (VORNDAM & KUNO, 1997).
For detection of antibodies class IgM, IgM-capture immunoenzymatic 
technique (MAC-ELISA), developed by KUNO et al. (1987) can be used, 
as well as the immunoenzymatic kits (ELISA) for IgM anti-dengue 
capture, provided that they have good sensitivity and specificity. For 
detection of antibodies IgG anti-dengue, both in-house techniques (GAC-
ELISA) and commercial kits for IgG-capture or indirect ones validated 
by reference centers can be used. 
For the quantification of hemagglutination inhibition antibodies (total: 
IgM and IgG), Hemagglutination Inhibition technique in microtechnique, 
adapted by CLARKE & CASALS (1958) can be used and this also serves 
to characterize the type of immune response, according to WHO criteria 
(CORDEIRO et al., 2007).
The neutralizing test by plaque reduction is the method considered 
“gold-standard” to determine DENV serotype-specific immunity, 
although new techniques to measure neutralizing antibodies are currently 
under development. This technique is recommended by the World 
Health Organization to assess the effectiveness of dengue vaccines in 
development (ROEHRING et al., 2008). 
The neutralizing activity in serum is determined by their ability 
to reduce the largest number of viral plaques. The positive sample 
is determined by a reduction of 50% or more in plaque formation 
(MORENS, 1985). Variations in the implementation of PRNT and the 
lack of standardization of the technique, which allows the use of a wide 
variety of cell lines, viral isolated from different sources, different cell 
culture media, etc., represent a limitation of the technique, and may 
produce different results, hampering the comparison of results between 
laboratories (ROEHRING et al., 2008). To circumvent this problem, 
WHO issued a guidance with recommendations to perform PRNT 
(WHO, 2007).
CONCLUSION
The results obtained with different techniques available for laboratory 
diagnosis of suspected dengue cases analyzed in our laboratory allowed 
us to observe significant differences in the sensitivity of some tests, some 
related to the time of illness of the patient, others with the characteristics 
of the infection (primary or secondary), presence or absence of IgM in 
the sample, etc. Thus, when a case of dengue is desired to be confirmed 
through laboratory tests, it is often required to use several techniques 
currently available and not restrict to a single methodology. 
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